Dougherty analyst Kyle Bauser initiated IntriCon with a Buy and $34 price target saying its a leading Medtech developer selling into compelling end markets. The analyst believes IntriCon remains highly undervalued given the company's world class manufacturing capabilities, high growth end markets, and upcoming catalysts. He expects the company's CGM business with Medtronic and its hearing aid business to accelerate in 2020 following new product launches and FDA hearing aid regulation. Further, catalysts from an update on new pipeline opportunities to diversify the portfolio, potential FDA draft document in the coming weeks, and revised company guidance could provide near-term upside for shares, Bauser wrote in a note to investors.